Safety and tolerability of antipsychotic treatment in young patients with schizophrenia.
Antipsychotics have proven efficacy for treating patients with early-onset schizophrenia, and aripiprazole, olanzapine, quetiapine, and risperidone have FDA approval for treating adolescents aged 13 to 17 years. Children and adolescents appear to have a higher risk than adults for experiencing adverse events such as extrapyramidal symptoms, prolactin elevation, weight gain, and metabolic effects when taking antipsychotic medications. Pediatric studies indicate that adverse effect profiles differ among commonly used antipsychotics. Clinicians should consider the differing adverse effect profiles when choosing medications for young patients.
From the Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, and the Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, USA.
SourceThe Journal of clinical psychiatry 72:8 2011 Aug pg e26
Pub Type(s)Interactive Tutorial